Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Observe validity of Recombinant Human Growth Hormone Injection assisted in IVF-ET (in vitro fertilization and embryo transfer) treatment of PCOS (polycystic ovary syndrome) patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GeneScience Pharmaceuticals Co., Ltd.
• Collaborator: Peking University Third Hospital
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Age between 25 and 35 years old, married female and infertile.

• BMI≥25kg/m2.

• Diagnosed as PCOS.

• No obvious chronic organic diseases, such as liver, kidney, heart, lung, thyroid, adrenal disease.

• Subjects do not take part in other clinical trial study within 3 months.

• The subjects sign the informed consent form.

Exclusion Criteria:

• BMI<25kg/m2.

• Hyperprolactinemia and congenital adrenal cortical hyperplasia.

• Diabetes, thyroid function hyperthyroidism, thyroid dysfunction, cushing's syndrome.

• Pelvic and peritoneal tumor and tumor secreting hyperandrogenism.

• Severe acute and chronic liver and kidney disease, such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity.

• Liver and kidney dysfunction, AST/ALT is 2.5 times higher than the normal limit, the serum of creatinine is 2 times higher than the normal level.

• Diseases affecting outcome of IVF pregnancy, eg, hydrosalpinx, hysteromyoma>4 cm, adenomyosis, endometriosis, endometrial cyst of ovary, unilateral ovary, tuberculosis of reproductive system.

• Allergic to E. coli. expression product and its excipients.

• Being involved in other drug clinical researchers.

• The researchers consider who is not suitable for the group.